STAT+: Next-gen Duchenne drug from Entrada disappoints

STAT PlusBiotech Next-gen Duchenne drug from Entrada disappoints Company is one of several trying to make improved exon-skipping treatments Manage alerts for this article Email this article Share this article By Jason MastMay 7, 2026 General Assignment Reporter Jason Mast[email protected]Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason on Signal at JasonMast.05. Entrada Therapeutics’ next-generation drug for Duchenne muscular dystrophy disappointed in an early trial, raising questions about the company’s competitiveness in an increasingly crowded field. Entrada is one of a group of companies developing new exon-skipping drugs. These medicines are designed to help patients with certain mutations produce shortened but still functional forms of dystrophin, the protein missing in Duchenne. Advertisement The first such drug, from Sarepta Therapeutics, had only marginal effects on protein production but was approved in 2016 under immense pressure from patient advocates. Since then, scientists have devised ways of redesigning these molecules to better infiltrate muscle cells, leading to vastly higher dystrophin levels. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, rare disease, STAT+ Submit a correction requestReprints Jason Mast General Assignment Reporter Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason on Signal at JasonMast.05. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended The Readout May 7, 2026 STAT Plus: FDA revisits a rare cancer treatment it rejected a few months ago Biotech May 7, 2026 STAT Plus: FDA to reconsider treatment for rare cancer after its surprise rejection Advertisement Adam's Biotech Scorecard May 7, 2026 STAT Plus: Color me skeptical: Drinking gold is not an ALS cure Biotech May 7, 2026 STAT Plus: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B The Readout May 6, 2026 STAT Plus: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price Subscriber Picks